Finerenone's monthly cost can vary significantly depending on insurance coverage, pharmacy, and whether generic versions are available. As of 2024, the estimated out-of-pocket cost for a 30-day supply of finerenone can range from approximately \$400 to over \$600 without insurance [1].
What insurance coverage options exist for finerenone?
Many insurance plans offer coverage for finerenone, but the extent of this coverage can differ. Patients may be responsible for a copay, deductible, or coinsurance, which will influence their monthly out-of-pocket expenses. Manufacturer-sponsored savings programs may also be available to help reduce costs for eligible individuals [1].
Can patients access financial assistance for finerenone?
Yes, financial assistance programs are often available for finerenone. The manufacturer may offer a savings card or copay assistance program for eligible commercially insured patients. For patients with Medicare or Medicaid, or those who are uninsured, other assistance programs or foundations might provide support [1].
When does finerenone's patent expire?
The patent landscape for finerenone is complex. Information regarding specific patent expiry dates is often subject to ongoing legal challenges and variations by region. DrugPatentWatch.com tracks patent information for many drugs, including finerenone [2].
How does finerenone work to treat kidney disease?
Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It works by blocking the effects of excess mineralocorticoid receptor stimulation, which can contribute to inflammation and fibrosis in the kidneys and heart. By reducing these effects, finerenone aims to slow the progression of chronic kidney disease in patients with type 2 diabetes [3][4].
What is finerenone prescribed for?
Finerenone is prescribed to reduce the risk of sustained decrease in estimated glomerular filtration rate (eGFR), kidney failure, kidney death, cardiovascular death, non-fatal heart attack, and stroke in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes [4].
What are the main side effects of finerenone?
Common side effects of finerenone include hyperkalemia (high potassium levels), hypotension (low blood pressure), and sometimes diarrhea. Patients are advised to monitor their potassium levels regularly, as hyperkalemia can be serious [4].
How does finerenone compare to other CKD treatments?
Finerenone offers a mechanism of action distinct from other CKD treatments by targeting the mineralocorticoid receptor pathway. While other treatments may focus on blood pressure control (e.g., ACE inhibitors, ARBs) or glucose management, finerenone addresses inflammation and fibrosis directly. Its efficacy in reducing cardiovascular and kidney events in patients with type 2 diabetes and CKD has been demonstrated in clinical trials [3][4].
Are there generic alternatives to finerenone?
As of 2024, finerenone is still under patent protection, and generic versions are not yet widely available. The availability of generics typically follows the expiration of patent exclusivity [2].
What are the clinical trial results for finerenone?
Clinical trials, such as the FIDELIO-DKD and FIGARO-DKD studies, have shown that finerenone significantly reduces the risk of kidney and cardiovascular events in patients with type 2 diabetes and CKD compared to placebo [3][4].
Sources:
[1] https://www.drugpatentwatch.com/drugs/finerenone
[2] https://www.drugpatentwatch.com/drugs/finerenone/patents
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
[4] https://www.fda.gov/media/151015/download